Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Metastatic Pancreatic Cancer
NCT01273805Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxychloroquine in pancreatic cancer (PC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: 2-month Progression-Free Survival Rate. Started Jan 2011; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01273805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01273805.